Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06282016

Risk Factors for Neuroendocrine Neoplasms

Recent studies show an increase in neuroendocrine neoplasms, especially for the digestive tract. Previous studies suggest various risk factors that were observed for various tumor sites, e.g. a family history of cancer, tobacco and alcohol consumption as well as metabolic disorders including diabetes and obesity. A risk factor that has been little studied to date is depressive disorders, which could increase the risk of neuroendocrine neoplasms either independently or through associated risk behaviors and/or antidepressant medication. The aim of this study is to identify risk factors for neuroendocrine neoplasms based on a case-control study in order to better understand the increase of neuroendocrine neoplasms in recent decades. The study is based on a record linkage of data from the Bavarian Cancer Registry and data from the Bavarian Association of Statutory Health Insurance Accredited Physicians. While the data from the Bavarian Cancer Registry enables the identification of neuroendocrine neoplasms on the basis of histopathological findings and thus is the basis for selecting cases, the claims data from the Bavarian Association of Statutory Health Insurance Accredited Physicians provides the source population as well data on diagnoses and thus enables the investigation of risk factors.

Recruiting

Interested in participating?

Request Info

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

Bavarian Cancer Registry, Bavarian Health and Food Safety Authority

Nuremberg, Bavaria, 90441, Germany

Location status: Recruiting

Location contact

Martin Meyer, Dr.

CONTACT

[email protected]

+49 (0)9131 6808-2920

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Persons with a statutory health insurance (about 85% of the population) and at least one outpatient physician contact in Bavaria between 2021 and 2023
  • Residence in Bavaria

Exclusion criteria

  • None

Treatment and study plan

Case-control study (no intervention)

Other

Observation of risk factors in cases and controls

Primary outcomes

  1. Assured NEN diagnosis of the BPS

    Time frame: 2021-2023

    Neuroendocrine neoplasm of the bronchopulmonary system

  2. Assured NEN diagnosis of the GEPS

    Time frame: 2021-2023

    Neuroendocrine neoplasm of the gastroenteropancreatic system

Secondary outcomes

  1. Assured NET diagnosis of the BPS

    Time frame: 2021-2023

    Neuroendocrine tumour of the bronchopulmonary system

  2. Assured NEC diagnosis of the BPS

    Time frame: 2021-2023

    Neuroendocrine carcinoma of the bronchopulmonary system

  3. Assured NET diagnosis of the GEPS

    Time frame: 2021-2023

    Neuroendocrine tumour of the gastroenteropancreatic system

  4. Assured NEC diagnosis of the GEPS

    Time frame: 2021-2023

    Neuroendocrine carcinoma of the gastroenteropancreatic system

Study contacts

Contact information is provided by the study sponsor or research team.

Jacqueline Müller-Nordhorn

CONTACT

[email protected]

+49-(0)9131-6808 ext. 4331

Sven Voigtländer

CONTACT

[email protected]

+49-(0)9131-6808 ext. 2927

Sponsors and collaborators

Lead sponsor

Bavarian Cancer Registry

Other Gov

Collaborators

  • Bavarian Association of Statutory Health Insurance Accredited Physicians

Registry information

Official study title

Risk Factors for Neuroendocrine Neoplasms: a Case-control Study Based on a Record Linkage of Registry and Claims Data

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Feb 28, 2024
Registry last updated
Jan 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.